Experienced in B-Cell Lymphoma

Mikael J. Eriksson

Karolinska Institutet
Stockholm, AB, SE 
Experienced in B-Cell Lymphoma
Karolinska Institutet
Stockholm, AB, SE 
OverviewLocationsClinical Research

Overview

Mikael Eriksson practices in Stockholm, Sweden. Mr. Eriksson is rated as an Experienced expert by MediFind in the treatment of B-Cell Lymphoma. His top areas of expertise are Breast Cancer, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Hormone Replacement Therapy (HRT), and Osteotomy.

His clinical research consists of co-authoring 307 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of B-Cell Lymphoma.

Gender
Male

Locations

Karolinska Institutet
Stockholm, AB, Sweden
Other Locations
Uppsala, C, Sweden
Karolinska Institutet
Solna, AB, Sweden
Lund, M, Sweden
Linkoeping, E 58183, Sweden
Huddinge, AB, Sweden
Oerebro, T 70185, Sweden
Sweden
Umea, AC, Sweden
Trollhaettan, O 46186, Sweden
Goeteborg, O, Sweden
Kalmar, H, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
View 1 Less Clinical Trial

306 Total Publications

Incorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model.
Incorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model.
Journal: JCO precision oncology
Published: September 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Eriksson's expertise for a condition
ConditionClose
View All 44 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile